From 21 days after the first dose of vaccine (the day of dose  2), 16  COVID-19  cases  were  confirmed  in  the  vaccine group (of 14964 participants; 0·1%) and 62 cases were  confirmed  in  the  placebo  group  (of  4902  participants;   1·3%);   vaccine   efficacy   was   91·6%   (95%   CI 85·6–95·2; table  2).  The  observed  vaccine  efficacy  was  greater than 87% in all age and sex subgroups. Notably, vaccine  efficacy  was  91·8%  (67·1–98·3)  in  participants  older than 60 years. There were no cases (vaccine group) and 20  cases  (placebo  group)  of  moderate  or  severe  COVID-19 confirmed at least 21 days after dose 1; thus, vaccine  efficacy  against  moderate  or  severe  COVID-19was 100% (94·4–100·0). From 15 to 21 days after the first dose,  efficacy  was  73·6%  (p=0·048),  then  from  day  21,  efficacy was 100% (p<0·0001; appendix p 11).

From 21 days after the first dose of vaccine (the day of dose  2), 16  COVID-19  cases  were  confirmed  in  the  vaccine group (of 14964 participants; 0·1%) and 62 cases were  confirmed  in  the  placebo  group  (of  4902  participants;   1·3%);   vaccine   efficacy   was   91·6%   (95%   CI 85·6–95·2; table  2).  The  observed  vaccine  efficacy  was  greater than 87% in all age and sex subgroups. Notably, vaccine  efficacy  was  91·8%  (67·1–98·3)  in  participants  older than 60 years. There were no cases (vaccine group) and 20  cases  (placebo  group)  of  moderate  or  severe  COVID-19 confirmed at least 21 days after dose 1; thus, vaccine  efficacy  against  moderate  or  severe  COVID-19was 100% (94·4–100·0). From 15 to 21 days after the first dose,  efficacy  was  73·6%  (p=0·048),  then  from  day  21,  efficacy was 100% (p<0·0001; appendix p 11).

Мне нужно, чтобы в нотпаде было читать удобно

@odomontois иди делай доклад

не дай бог хуйню сделаешь

а кто как решает задачи с джобами

примерный план доклада такой